This website and all information, services, products, and materials available on it are provided on an “as is” basis, without any warranty. To the fullest extent allowed by law, Torque Pharma does not make any express or implied guarantee about the website’s operation, availability, accuracy, completeness, or content. Torque Pharma will not be responsible for any direct, indirect, incidental, consequential, special, or punitive loss or damage arising from the use of this website or any information, product, or service available through it, even if the possibility of such damage has been communicated.
All medical, health, product, and treatment information on this website is provided for general information only and may be presented in a summarised form. It is not a substitute for advice from a qualified medical practitioner or for the instructions, warnings, and information provided on product packaging or labels. Do not use this website to diagnose a health condition or to select, prescribe, change, or stop any treatment. Always consult a qualified healthcare professional and carefully read the approved product label and packaging information before using any Torque Pharma product.
Get helpful answers before exploring the complete range.
Not necessarily. Long-term uric acid control and short-term flare relief are separate aspects of gout management.
Torque Pharma lists Febutor in 40 mg and 80 mg tablet strengths, each with separate approved product information.
No. They contain different active ingredients, perform different therapeutic roles, and should be considered according to their individual product information.
Long-term treatment focuses on controlling uric acid, while flare management focuses on reducing sudden pain, swelling, and inflammation.
No. Febutor belongs to the long-term urate-lowering category and is not positioned as an immediate pain-relief formulation.
